

## Special Issue

# Innovations in Soft Tissue Sarcoma Diagnosis and Treatment

### Message from the Guest Editors

Recent advances in genetic screening, molecular profiling, targeted therapy, gene therapy and immunotherapy for soft tissue sarcomas (STS) have evoked increasing optimism in the medical and scientific community. Hence, it is time to reflect on the many faces of STS and current innovations in its diagnosis and treatment. STS is a rare cancer involving mesodermal tissues. Surgical resection is the standard of care for localized disease, but its recurrence rate is high and the prognosis for advanced STS is poor, with a median survival of 8–13 months. This Special Issue entitled "Innovations in Soft Tissue Sarcoma Diagnosis and Treatment" will include review articles, original clinical and translational research articles that are hypothesis-generating toward the development of precision medicine for STS.

---

### Guest Editors

Dr. Erlinda M. Gordon  
Dr. Sant P. Chawla  
Dr. Frederick L. Hall

---

### Deadline for manuscript submissions

closed (30 May 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/123049](https://mdpi.com/si/123049)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)